This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Fortress Biotech (FBIO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fortress' (FBIO) Partner Meets Study Goal for Menkes Disease
by Zacks Equity Research
Cyprium Therapeutics, a partner company of Fortress Biotech (FBIO), reports positive data from two pivotal studies evaluating CUTX-101 in patients with Menkes disease.
Fortress Biotech (FBIO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fortress Biotech (FBIO) delivered earnings and revenue surprises of 71.43% and 29.11%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Fortress Biotech (FBIO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Biotech Stocks Set to Outpace Q1 Earnings Estimates
by Zacks Equity Research
Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.
GT Biopharma (GTBP) to Report Q1 Earnings: What to Expect?
by Zacks Equity Research
GT Biopharma (GTBP) is expected to provide updates on its pipeline development when it reports first-quarter 2021 result.
Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Is the Options Market Predicting a Spike in Fortress Biotech (FBIO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Fortress Biotech (FBIO) stock based on the movements in the options market lately.
Fortress Biotech (FBIO) Surges 11.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
Fortress Biotech (FBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Will Fortress Biotech (FBIO) Report Negative Q4 Earnings? What You Should Know
by Zacks Equity Research
Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fortress Biotech (FBIO) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Fortress Biotech (FBIO) delivered earnings and revenue surprises of 28.57% and -14.31%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Fortress Biotech (FBIO) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fortress Biotech (FBIO) Enters Oversold Territory
by Zacks Equity Research
Fortress Biotech (FBIO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
Fortress Biotech Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Fortress Biotech has been struggling lately, but the selling pressure may be coming to an end soon.
Will Fortress Biotech to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor Fortress Biotech.
All You Need to Know About Fortress Biotech (FBIO) Rating Upgrade to Strong Buy
by Zacks Equity Research
Fortress Biotech (FBIO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Sarepta (SRPT) Jumps: Stock Rises 8.3%
by Zacks Equity Research
Sarepta (SRPT) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Fortress Biotech (FBIO) in Focus: Stock Moves 6.5% Higher
by Zacks Equity Research
Fortress Biotech (FBIO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
Fortress Biotech (FBIO) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Fortress Biotech (FBIO) delivered earnings and revenue surprises of 37.29% and -1.83%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Fortress Biotech (FBIO) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fortress Biotech (FBIO) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Fortress Biotech (FBIO) delivered earnings and revenue surprises of 25.37% and 30.46%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Moving Average Crossover Alert: Fortress Biotech, Inc. (FBIO)
by Zacks Equity Research
Moving Average Crossover Alert: Fortress Biotech, Inc. (FBIO)
Fortress Biotech (FBIO) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Fortress Biotech Inc (FBIO).
Fortress Biotech (FBIO) Looks Good: Stock Adds 5% in Session
by Zacks Equity Research
Fortress Biotech, Inc. (FBIO) shares rose over 5% in the last trading session.
Fortress Biotech (FBIO) Catches Eye: Stock Moves Up 8.3%
by Zacks Equity Research
Fortress Biotech, Inc. (FBIO) moved big last session, as its shares rose over 8% on the day.